Stomach Cancer Market

The stomach cancer market is anticipated to expand from US$ 5.15 billion in 2024 to US$ 11.98 billion by 2031, with a projected CAGR of 14.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Stomach cancer, or gastric cancer, arises from the abnormal and uncontrolled proliferation of malignant cells in the stomach. Factors contributing to the risk of stomach cancer include age and dietary habits. Symptoms may include indigestion, stomach pain, loss of appetite, heartburn, and weight loss. Treatment options for stomach cancer include chemotherapy, radiation therapy, and immunotherapy. The growth of the stomach cancer market is driven by the rising incidence of the disease, advancements in treatment modalities such as chemotherapy, surgery, and targeted therapies, as well as ongoing research and development aimed at enhancing patient outcomes. With a growing focus on early diagnosis and personalized treatment strategies, the stomach cancer treatment market is expected to continue its growth trajectory in the coming years.

Growth Catalysts:Healthcare companies are engaging in various research and development initiatives to create innovative treatments for gastric cancer. Furthermore, these treatments are undergoing evaluation in clinical trials, with new methodologies being continuously developed and explored. Some notable products in the pipeline include:

In December 2022, Zhejiang Doer Biologics Co., Ltd entered into a clinical trial collaboration with Merck & Co., Inc. to assess Doer Bio's anti-Claudin18.2 antibody DR30303 in conjunction with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with gastric or gastroesophageal junction cancer. The agreement stipulated that Doer Bio would conduct an experimental study based on a mutually agreed protocol to evaluate the safety and efficacy of DR30303 combined with KEYTRUDA in Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer patients.In November 2022, Triumvira Immunologics announced preclinical findings for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, along with data on HER2-specific TAC-T products. The company presented updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 for gastric cancer treatment.In September 2022, Nuvectis Pharma, Inc. reported positive results for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. Tumor volumes were assessed over 28 days after treatment with either a vehicle or NXP800, showing tumor regression and significant growth inhibition compared to the control.Thus, the increasing number of clinical trials enhances the availability of gastric cancer treatments globally, positively influencing the growth of the stomach cancer market.

Strategic Insights Report Segmentation and Scope:The stomach cancer market is segmented by type, treatment, route of administration, distribution channel, and geography. By type, it includes adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. In terms of treatment, the market is classified into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. The market is segmented by route of administration into oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is divided into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The stomach cancer market is categorized by type into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a substantial market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By treatment, the market is divided into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. In 2022, the chemotherapy and combination drugs segment accounted for a significant market share, while the targeted and immunotherapy drugs segment is expected to show the highest CAGR from 2022 to 2030.

Regarding the route of administration, the market is segmented into oral, parenteral, and others. The oral segment held a notable market share in 2022 and is anticipated to grow at the fastest CAGR during 2022-2030.

In terms of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant market share in 2022 and is expected to register the highest CAGR during 2022-2030.

Regional Analysis:The stomach cancer market is primarily segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant market share, with the US holding the largest share in the region. The growth of the market in North America is attributed to the rising prevalence of gastric cancer, increased adoption of targeted cancer therapies, and the availability of advanced technologies in cancer research and treatment facilities. The American Cancer Society projected approximately 26,500 new cases of gastric cancer (15,930 in males and 10,570 in females) to be diagnosed in 2023, with around 11,130 deaths (6,690 males and 4,440 females) expected due to gastric cancer. North America is well-equipped with advanced treatment options for cancer, and companies are striving to compete with established players in the region.

Additionally, the growing number of clinical trials aimed at developing effective drugs for gastric cancer patients, along with an increase in product launches and approvals, is expected to drive market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-based chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Such developments are likely to support market growth in the region during the forecast period.

Stomach Cancer Market Report Scope Industry Developments and Future Opportunities:Several initiatives by key players in the global stomach cancer market are highlighted below:

In January 2021, AstraZeneca and Daiichi Sankyo Company received FDA approval for Enhertu to treat adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.

Competitive Landscape and Key Companies:Prominent players in the stomach cancer market include Bristol Myers Squibb Company, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Biocon, Teva Pharmaceutical Industries Ltd, Celltrion Healthcare Co., Ltd, Samsung Bioepis, Pfizer Inc., and Ipsen Pharma. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global demand.